Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Livtencity (maribavir) is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• In kidney transplant recipients (KTRs), prophylaxis significantly reduced CMV infection (pOR 0.33; 95% CI: 0.19, 0.57) and CMV disease (pOR 0.27; 95% CI: 0.19, 0.39) compared to no prophylaxis but was associated with higher rates of late CMV infection and hematological adverse events, including leukopenia (pOR 2.93; 95% CI: 1.22, 7.04).
• Preemptive therapy (PET) in KTRs resulted in lower rates of CMV disease (pOR 0.29; 95% CI: 0.11, 0.77) and reduced medical costs compared to no PET, with fewer hematological adverse events compared to prophylaxis.
• Maribavir demonstrated effectiveness in managing refractory or resistant HCMV infections in transplant recipients, whereas Letermovir was effective in preventing CMV in hematopoietic stem cell transplant recipients.
• There is no specific safety information available regarding Maribavir in the reviewed studies.
• There is no population types or subgroups information available in the reviewed studies.